A Phase 1 interventional study of LY2963016 and Lantus in Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 1 site in Singapore. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-07.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 81 studies testing Insulin Glargine in Diabetes Mellitus — 2 open to participants now, 2 under way, none of them phase 3. Insulin Glargine · Diabetes Mellitus.
Among the 81 studies testing Insulin Glargine in Diabetes Mellitus, this one is the 72nd largest by enrollment, is one of 11 that started in 2011, is one of 13 in phase 1, and was the 55th registered.
8,295 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 81 studies testing Insulin Glargine in Diabetes Mellitus are open now, in 2 countries. Recruiting first, the newest first:
Rutgers, The State University of New Jersey · Sites in United States
Ages 18–50 · Women only
Medical University of Warsaw · Sites in Poland
Ages 18+
By country, each count listing its studies:
Insulin Glargine: first FDA approval 2000 (LANTUS SOLOSTAR), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.
This study: 21 Years to 60 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
81 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 11 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 80 across 6,026 interventional studies indexed under Diabetes Mellitus.
Median enrollment 80 across the 81 interventional studies. Of the 75 that completed or were terminated, 31 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 81 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
48 studies in Diabetes Mellitus by Eli Lilly and Company: none open now, 4 under way, 1 of them phase 3. Of 43 finished, 35 (81%) have results posted.
Among the 48 studies in Diabetes Mellitus by Eli Lilly and Company, this one is the 45th largest by enrollment of the 47 interventional ones that give a count, is one of 12 that started in 2011, is one of 5 in phase 1, and was the 22nd registered.
Eli Lilly and Company’s Diabetes Mellitus studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 81 studies testing Insulin Glargine in Diabetes Mellitus, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 48 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin. The study will also gather information on the safety and tolerability of LY2963016 in healthy subjects. The study is approximately 12 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single 0.5-unit per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously.
Drug: LY2963016
A single 0.5-U/kg dose of Lantus will be administered subcutaneously.
Drug: Lantus
Administered subcutaneously
Administered subcutaneously
Also known as: Insulin Glargine
Pharmacokinetics: Area Under the Concentration-Time Curve (AUC)
AUC from time zero to 24 hours (AUC0-24) is reported for this outcome measure.
Time frame: Periods 1 and 2: Baseline up to 24 hours
Pharmacokinetics: Maximum Concentration (Cmax)
Time frame: Periods 1 and 2: Baseline up to 24 hours
Maximum Glucose Infusion Rate (Rmax)
Time frame: Periods 1 and 2: Baseline up to 24 hours
Total Glucose Infused (Gtot)
Time frame: Periods 1 and 2: Baseline up to 24 hours
Time of Maximum Glucose Infusion Rate (tRmax)
Time frame: Periods 1 and 2: Baseline up to 24 hours
Number of Participants With Clinically Significant Effects
Clinically significant effects were defined as serious and nonserious adverse events. A summary of serious and all other nonserious adverse events is located in the Reported Adverse Event module.
Time frame: Baseline up to 30 days
| Milestone | LY2963016 First, Then Lantus | Lantus First, Then LY2963016 |
|---|---|---|
| Started | 11 | 5 |
| Received at least 1 dose of ly2963016 | 11 | 5 |
| Completed | 11 | 5 |
| Not completed | 0 | 0 |
| Milestone | LY2963016 First, Then Lantus | Lantus First, Then LY2963016 |
|---|---|---|
| Started | 11 | 5 |
| Completed | 10 | 5 |
| Not completed | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 |
| Milestone | LY2963016 First, Then Lantus | Lantus First, Then LY2963016 |
|---|---|---|
| Started | 10 | 5 |
| Completed | 8 | 5 |
| Not completed | 2 | 0 |
| Withdrew: Adverse event | 2 | 0 |
AUC from time zero to 24 hours (AUC0-24) is reported for this outcome measure.
| picomole*hour per liter (pmol*hr/L) | LY2963016 | Lantus |
|---|---|---|
| Pharmacokinetics: Area Under the Concentration-Time Curve (AUC) | 1900 ± 22 | 2180 ± 30 |
| picomole per liter (pmol/L) | LY2963016 | Lantus |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) | 110 ± 26 | 130 ± 35 |
| grams per hour (g/h) | LY2963016 | Lantus |
|---|---|---|
| Maximum Glucose Infusion Rate (Rmax) | 10.2 ± 50 | 11.3 ± 32 |
| gram (g) | LY2963016 | Lantus |
|---|---|---|
| Total Glucose Infused (Gtot) | 141 ± 54 | 160 ± 36 |
| hour (h) | LY2963016 | Lantus |
|---|---|---|
| Time of Maximum Glucose Infusion Rate (tRmax) | 10.5 (5.40 to 15.1) | 10.2 (5.50 to 15.8) |
Clinically significant effects were defined as serious and nonserious adverse events. A summary of serious and all other nonserious adverse events is located in the Reported Adverse Event module.
| participants | LY2963016 | Lantus |
|---|---|---|
| Serious Adverse Events | 0 | 0 |
| Nonserious Adverse Events | 8 | 6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY2963016 | — | 0/16 (0%) | 8/16 (50%) |
| Lantus | — | 0/13 (0%) | 6/13 (46.2%) |
| Event | LY2963016 | Lantus |
|---|---|---|
| Catheter site swellingGeneral disorders | 3/16 | 1/13 |
| DizzinessNervous system disorders | 2/16 | 0/13 |
| Dry mouthGastrointestinal disorders | 0/16 | 1/13 |
| VomitingGastrointestinal disorders | 0/16 | 1/13 |
| Catheter site painGeneral disorders | 1/16 | 1/13 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/16 | 1/13 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 0/16 | 1/13 |
| RashSkin and subcutaneous tissue disorders | 0/16 | 1/13 |
| PalpitationsCardiac disorders | 1/16 | 0/13 |
| NauseaGastrointestinal disorders | 1/16 | 0/13 |
| Age, Continuous(years) | Entire Study Population |
|---|---|
| Mean | 31.1 ± 7.6 |
| Sex: Female, Male(Participants) | Entire Study Population |
|---|---|
| Female | 3 |
| Male | 13 |
| Ethnicity (NIH/OMB)(Participants) | Entire Study Population |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 16 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Entire Study Population |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 14 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 2 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(participants) | Entire Study Population |
|---|---|
| Singapore | 16 |
The record gives a start of Jun 2011, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2014, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Insulin Glargine